Zealand Pharma submits NDA for hyperinsulinism drug dasiglucagon
The NDA includes pivotal data from Phase III trials and a long-term extension, with one trial missing its primary endpoint.
The NDA includes pivotal data from Phase III trials and a long-term extension, with one trial missing its primary endpoint.
What's Your Reaction?
